Patents Assigned to IASON GmbH
  • Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
    Patent number: 9809624
    Abstract: The invention relates to a new neurotensin analogue, or a salt thereof, useful for targeting to neurotensin receptor-positive tumors, like ductal pancreatic adenocarcinoma, exocrine pancreatic cancer, invasive ductal breast cancers, colon adenocarcinoma, small cell lung carcinoma, Ewing sarcoma, meningioma, medulloblastoma and astrocytoma.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 7, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), IASON GmbH
    Inventors: Anne Gruaz, Didier Pelaprat, Jacques Barbet, Dirk Tourwe